^
Association details:
| Biomarker: | DLL3 expression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | tarlatamab (AMG 757) (CD3 agonist, DLL3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OA11.03 - A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Published date:
01/12/2021
Excerpt:
DLL3 expression at any level was observed in 31/32 (96.9%) patient tumor samples, with overall H-score 40–300. Tumor shrinkage occurred across a wide range of DLL3 expression (H-score, 55–300)….AMG 757 has acceptable safety at doses of up to 10 mg and shows anti-tumor activity in patients with SCLC.
Trial ID:
Source:
Title:
P15.01 - AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
Published date:
01/12/2021
Excerpt:
We evaluated the efficacy and pharmacodynamic effects of AMG 757 treatment in three preclinical models of SCLC that express DLL3...In the orthotopic SHP-77 model, AMG 757 treatment led to significant tumor growth inhibition in the lungs relative to treatment with a control HLE BiTE molecule...AMG 757–mediated redirected T-cell lysis can drive significant antitumor activity in established SCLC tumor models.
Source:
Title:
The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer
Published date:
11/09/2020
Excerpt:
AMG 757 induced T cell activation, cytokine production, and potent T cell redirected killing of DLL3-expressing SCLC, neuroendocrine prostate cancer, and other DLL3-expressing NET cell lines in vitro.
DOI:
10.1136/jitc-2020-SITC2020.0627
Source:
Title:
Abstract 4558: Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)
Published date:
05/15/2020
Excerpt:
We evaluated the efficacy and pharmacodynamic (PD) effects of AMG 757 in three preclinical models of SCLC that express DLL3….In the LXFS 1129 PDX model, treatment with AMG 757 induced complete tumor regression in 8 out of 10 mice, whereas treatment with the control HLE BiTE molecule showed no tumor growth inhibition. In the orthotopic SHP-77 model, treatment with AMG 757 led to significant tumor growth inhibition in the lungs relative to treatment with a control HLE BiTE molecule; the bioluminescence (BLI) signal decreased to near the limit of detection 22 days after start of treatment.
DOI:
10.1158/1538-7445.AM2020-4558
